AngioDynamics Appoints Interim CFO to Permanent Position

AngioDynamics Inc., a provider of minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, has appointed Stephen Trowbridge as executive vice president and chief financial officer (CFO).
 
Trowbridge has served as the company’s interim CFO since Oct. 22, 2019, in addition to his responsibilities as senior vice president and general counsel. AngioDynamics will initiate a search for the role of general counsel; to facilitate a smooth transition, Trowbridge will retain his duties as general counsel until a replacement is named.
 
“We are thrilled to have Steve assume the CFO role full-time and lead our outstanding finance organization,” said Jim Clemmer, AngioDynamics president and CEO. “Steve and I have worked together for several years, and I have experienced first-hand his leadership, talent, and passion for our business and patients. I’m confident that the unique insights Steve has developed during his 11 years at AngioDynamics will be instrumental as we continue our transformation into a more technology-focused medical device company.”
 
Trowbridge joined AngioDynamics as corporate counsel in 2008, was promoted to vice president and general counsel in 2010, and subsequently promoted to senior vice president, general counsel in 2013. Prior to AngioDynamics, Trowbridge served as corporate counsel at Philips Healthcare and Intermagnetics General Corporation. Trowbridge began his career with Cadwalader, Wickersham & Taft LLP in the firm’s Mergers and Acquisitions and Securities Group.
 
Trowbridge earned a bachelor of science degree in science and technology studies from Rensselaer Polytechnic Institute, a juris doctor from the University of Pennsylvania Law School, and an MBA from Duke University’s Fuqua School of Business.

“I am excited to assume the CFO role on a permanent basis,” said Trowbridge. “I look forward to continuing to work closely with Jim and the rest of the team as we enter larger, faster-growing markets and bring innovative new products to healthcare professionals and patients around the globe.”
 
In January, AngioDynamics launched the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05), a pilot study to evaluate the safety and efficacy of the company’s AURYON Atherectomy System in the treatment of de novo, re-stenotic, and in-stent restenosis (ISR) lesions in infrainguinal arteries of patients with Peripheral Artery Diseases (PAD).
 
The AURYON Atherectomy System, previously known as the Eximo B-Laser, is a proprietary 355nm wavelength laser-technology platform that was acquired by AngioDynamics in October 2019.
 
“The PATHFINDER I study will provide valuable, scientifically backed data to further differentiate the AURYON system from competitive products in this space and build upon the excellent long-term results that patients experienced during the IDE,” said Juan Carlos Serna, AngioDynamics vice president for Clinical Affairs & Healthcare Economics.
 
AngioDynamics’ PATHFINDER I Registry is a prospective, non-randomized, single arm, multicenter observational study that will evaluate the performance of the AURYON Atherectomy System during procedures and measure clinical outcomes, both intermediate and long-term. A total of 100 eligible PAD patients treated with the AURYON Atherectomy System in a post-market setting will be enrolled and tracked for a 36-month period after the initial procedure.